Heron Therapeutics (HRTX) Liabilities and Shareholders Equity (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $246.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 4.44% year-over-year to $246.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $983.1 million (up 8.3% YoY) and the FY2025 annual result came in at $255.9 million, up 9.75% from the prior year.
• Liabilities and Shareholders Equity eased to $246.2 million in Q1 2026, from $255.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $273.7 million in Q1 2022 to a low of $201.2 million in Q2 2023.
• A 5-year average of $236.7 million and a median of $233.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 39.65% — and 2025, when it gained 12.76%.
• Tracing HRTX's Liabilities and Shareholders Equity over 5 years: stood at $251.0 million in 2022, then fell by 11.33% to $222.5 million in 2023, then increased by 4.78% to $233.1 million in 2024, then advanced by 9.75% to $255.9 million in 2025, then decreased by 3.78% to $246.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $246.2 million (Q1 2026), $255.9 million (Q4 2025), and $249.0 million (Q3 2025), per Business Quant data.